Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Transactions
Holdings
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
Appointed director
Sonoma Pharmaceuticals, Inc. (SNOA) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/08/2018 8-K Quarterly results
Docs: "Sonoma Pharmaceuticals Reports Record Revenue in Second Quarter FY 2019 · Total Revenue of $4.9 Million, up 13% over June 2018 Quarter · Total Revenue up 14% over September 2017 Quarter Conference Call Begins at 4:30 pm EST Today",
"Presentation used by Sonoma Pharmaceuticals, Inc. on November 8, 2018"
06/13/2018 8-K Quarterly results
Docs: "Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2018 Financial Results Strong Annual Year-Over-Year Growth in Revenue of 30% $10 Million in Cash as of March 31, 2018 Conference Call Begins at 4:30pm EDT Today",
"Presentation used by Sonoma Pharmaceuticals, Inc. on June 13, 2018"
02/07/2018 8-K Quarterly results
Docs: "Sonoma Pharmaceuticals Reports Record Total Revenue of $4.8 million for Third Quarter FY 2018 with Year over Year Product Revenue Growth of 46% · Product revenue up 12% compared to September 2017 quarter · U.S. product revenue up 27% compared to the September 2017 quarter · Cash on hand equals $8.6 million at quarter end Conference Call Begins at 4:30pm EST Today Slide Presentation to Review in Tandem with Earnings Call Available at http://ir.sonomapharma.com/events.cfm",
"Presentation used by Sonoma Pharmaceuticals, Inc. on February 7, 2018"
11/09/2017 8-K Quarterly results
Docs: "Sonoma Pharmaceuticals Reports Robust Top Line Growth for Second Quarter FY 2018 with 61% Product Revenue Growth and Total Revenue of $4.3 Million · Product revenue up 15%, compared to the June 2017 quarter · Prescriptions filled were up 42% over last year and up 14% over the June 2017 quarter to 19,660 · EBITDA loss reduced to $2.3 million · Cash on hand equals $10 million Conference Call Begins at 4:30pm EST Today Slide Presentation to Review in Tandem with Earnings Call Available at http://ir.sonomapharma.com/events.cfm",
"Presentation used by Sonoma Pharmaceuticals, Inc. on November 9, 2017"
08/08/2017 8-K Quarterly results
Docs: "Sonoma Pharmaceuticals Reports Financial Results for First Quarter of Fiscal Year 2018 · Product revenue for first quarter up 49%, compared to the same period last year, driven by growth in U.S. dermatology sales Conference Call Begins at 4:30pm EDT Today"
06/05/2017 8-K Form 8-K - Current report
02/09/2017 8-K Form 8-K - Current report
11/10/2016 8-K Form 8-K - Current report
07/28/2016 8-K Form 8-K - Current report
06/16/2016 8-K Form 8-K - Current report
02/04/2016 8-K Form 8-K - Current report
11/05/2015 8-K Quarterly results
Docs: "Oculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2016 Total Revenue of $4.1 Million Increased 24%—Led by 64% Increase in Product Revenue—Driven by Growth in U.S. Dermatology Sales Conference Call at 4:30 pm ET Today"
07/30/2015 8-K Quarterly results
Docs: "Oculus Innovative Sciences Reports Financial Results for the First Quarter of Fiscal Year 2016 · U.S. dermatology and Latin American sales drive 37% product revenue growth · FDA 510k clearance for treatment of atopic dermatitis with a unique “no touch” spray gel · Cash as of June 30, 2015 of $8.8 million and debt free Conference call begins at 4:30 p.m. EDT today"
06/11/2015 8-K Quarterly results
Docs: "Oculus Innovative Sciences Reports Financial Results for the Fourth Quarter of Fiscal Year 2015"
11/13/2014 8-K Quarterly results
Docs: "Oculus Innovative Sciences Reports Financial Results for the Second Quarter of Fiscal Year 2015 · Total revenue of $3.3 million for the second quarter · Net loss of $718,000, reduced from $1.4 million in same period last year · Oculus owns two million shares of Ruthigen · Net worth of $13.4 million, up $11.9 million from September 30, 2013 Conference Call Begins at 4:30 p.m. Today"
08/07/2014 8-K Quarterly results
Docs: "Oculus Innovative Sciences Reports Revenues of $3.4 Million and Net Loss of $70,000 for First Quarter of Fiscal 2015 · Net loss of $70,000, reduced $1.6 million from same period last year · Oculus owns two million shares of Ruthigen · Net worth of $13.4 million, up $10.8 million from June 30, 2013 · Cash position of $5 million with $64,000 in debt Conference Call Begins at 4:30 p.m. Today"
06/12/2014 8-K Quarterly results
Docs: "Oculus Innovative Sciences Reports Revenues of $2.9 Million and Net Income of $7.5 Million for Fourth Quarter of Fiscal 2014 Primarily Due to Accounting Treatment of Ruthigen IPO Transaction · Oculus’ subsidiary, Ruthigen, completes IPO, raising net proceeds of approximately $15.5 million · Oculus owns two million shares of Ruthigen and net worth increased $8.0 million to $12.1 million primarily as a result of the Ruthigen transaction · More Pharma, Oculus’ sales partner in Mexico, launches Microcyn-based products in Mexican oral/dental markets Conference Call Begins at 4:30 p.m. Today"
02/13/2014 8-K Quarterly results
Docs: "Oculus Innovative Sciences Reports Revenues of $3.3 Million for Third Quarter of Fiscal 2014 · Microcyn® Scar Management HydroGel Approved by FDA in U.S. and Ministry of Health in Mexico During Quarter · Reduced $3.0 Million Debt-Related Liability During Quarter to $50,000 · Signed Internal Agreements with Ruthigen, Enabling IPO and Capping Reimbursable IPO-Related Expenses Conference Call Begins at 4:30 p.m. Today"
11/19/2013 8-K Quarterly results
Docs: "Oculus Innovative Sciences Reports Revenues of $4.1 Million for Second Quarter of Fiscal 2014, Meeting Guidance of Greater than $3.6 Million EBITDAS for second quarter was , including $994,000 of Ruthigen-related expenses in the quarter, resulting in a positive EBITDAS of $112,000 on a pro forma basis, excluding Ruthigen expenses Conference Call Begins at 4:30 p.m. Today"
08/08/2013 8-K Form 8-K - Current report
06/13/2013 8-K Quarterly results
Docs: "Oculus Innovative Sciences Reports Revenues of $15.5 Million for Fiscal Year 2013, Product Revenue up 23 Percent · EBITDAS for fiscal 2013 improved by $1.8 million to million including $410,000 of one-time severance costs related to the More Pharma transaction and $457,000 expenses related to Ruthigen · Cash position of $7.9 million at March 31, 2013, up $3.2 million from March 31, 2012 · Revenue for fourth quarter of fiscal 2013 of $3.3 million · Oculus’ wholly owned subsidiary, Ruthigen, files confidential registration statement on Form S-1 on May 24, 2013 Conference Call Begins at 4:30 p.m. Today"
02/13/2013 8-K Quarterly results
Docs: "Oculus Innovative Sciences Reports Revenues of $3.5 Million for the Third Quarter of Fiscal 2013 · Oculus board of directors unanimously approved a plan to spin off the company’ s novel drug RUT58-60 as a separate company to be called Ruthigen, Inc. in January 2013 · Oculus’ subsidiary, Ruthigen, to pursue a FDA drug indication for U.S. surgical and trauma market and seek partnerships in Europe and Japan · Revenue for the third quarter of fiscal 2013 of $3.5 million, up 27% · EBITDAS for the third quarter of fiscal 2013 of · Revenue for nine months of fiscal 2013 of $12.1 million, up 29% · EBITDAS for nine months of fiscal 2013 improved by $2.0 million to with $410,000 of one-time severance costs related to the More Pharma transaction · Cash..."
11/01/2012 8-K Form 8-K - Current report
08/02/2012 8-K Form 8-K - Current report
06/07/2012 8-K Form 8-K - Current report
02/02/2012 8-K Form 8-K - Current report
11/03/2011 8-K Form 8-K - Current report
08/04/2011 8-K Form 8-K - Current report
06/02/2011 8-K Form 8-K - Current report
02/03/2011 8-K Form 8-K - Current report
11/04/2010 8-K Form 8-K - Current report
08/05/2010 8-K Form 8-K - Current report
06/03/2010 8-K Form 8-K - Current report
02/04/2010 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy